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Abstract
: We and others have shown a significant proportion ofBackground
interventional trials registered on ClinicalTrials.gov have their primary outcomes
altered after the listed study start and completion dates. The objectives of this
study were to investigate whether changes made to primary outcomes are
associated with the likelihood of reporting a statistically significant primary
outcome on ClinicalTrials.gov.
: A cross-sectional analysis of all interventional clinical trialsMethods
registered on ClinicalTrials.gov as of 20 November 2014 was performed. The
main outcome was any change made to the initially listed primary outcome and
the time of the change in relation to the trial start and end date.
: 13,238 completed interventional trials were registered withFindings
ClinicalTrials.gov that also had study results posted on the website. 2555
(19.3%) had one or more statistically significant primary outcomes. Statistical
analysis showed that registration year, funding source and primary outcome
change after trial completion were associated with reporting a statistically
significant primary outcome.
 Funding source and primary outcome change after trialConclusions:
completion are associated with a statistically significant primary outcome report
on clinicaltrials.gov.
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Table 1. Association of funding status and primary outcome 
change after trial completion with reporting a statistically 
significant primary outcome.
Odds Ratio (95% 
confidence interval) P value
Public funding 1
Mixed funding 0.79 (0.67–0.94) 0.008
Industry funding 1.39 (1.25–1.54) <0.001
No primary outcome 
change 1
Primary outcome change 
after completion date 1.53 (1.12–2.10) 0.008
Registration year (per 
additional year) 0.97 (0.95–0.99) 0.006
Introduction
Clinical trials provide the principal method with which to assess the 
effectiveness of therapeutic strategies1. An important principle in 
the good conduct of clinical trials is that a summary of the trial pro-
tocol, with a pre-defined primary outcome, should be freely avail-
able before the study commences1. In February 2000, the United 
States (US) Food and Drug Administration (FDA) created an online 
clinical trials registry named ClinicalTrials.gov2. We and others 
have shown a significant proportion of interventional trials regis-
tered on ClinicalTrials.gov have their primary outcomes altered 
after the listed study start and completion dates3,4. In this extended 
analysis, we sought to investigate whether changes made to primary 
outcomes are associated with the likelihood of reporting a statisti-
cally significant primary outcome on ClinicalTrials.gov.
Methods
We used R (http://cran.r-project.org/web/packages/rclinicaltrials/
vignettes/basics.html) to download data from all completed inter-
ventional clinical studies registered with ClinicalTrials.gov as of 
20th November 2014, as previously described3. New to this study, 
we also downloaded data concerning study results for these trials; 
specifically the ‘p value’ fields from the ‘study results’ tab for pri-
mary outcomes.
We searched for potential non-inferiority studies by text searching 
for the word inferiority in the title.
Changes in primary outcomes were defined as previously described3. 
A study was classified as not having a primary outcome changed if 
the original primary outcome was listed as ‘same as current’. Probable 
funding source was derived using the algorithm previously described3.
A trial having a statistically significant primary outcome was 
defined as a trial having a P value less than 0.05 in the p value field 
in the study results tab for any primary outcome.
We used logistic regression to calculate odds ratios (ORs) and 95% 
confidence intervals (95% CI) for comparisons between significant 
primary outcome and non-significant primary outcome groups, 
using registration date, primary outcome change after study com-
pletion and funding source as explanatory variables. P-values <0.05 
were interpreted as significant. Statistical analyses were conducted 
using the STATA 12.0.0 software.
Results
Dataset 1. Dataset of funding source, primary outcome 
changes and statistical significance of clinical trials registered 
on ClinicalTrials.org. 
http://dx.doi.org/10.5256/f1000research.6312.d45056
All clinical studies classified as ‘interventional studies’ registered 
with ClinicalTrials.gov as of 20th November 2014 are shown. 
Probable funding source was derived using the algorithm 
previously described3. A statistically significant primary outcome 
was defined as a trial having a P value less than 0.05. 1=yes; 
0=no; blank=no info in all columns except “studyphase” and 
“sponsortype (0=public; 1=industry; 2=mixed). pom: primary 
outcome measure; sig: significance.
As of 20 November 2014, 13,238 completed interventional trials 
were registered with ClinicalTrials.gov that also had study results 
posted on the website. The trials were registered between 1999 
and 2014 and 2555 (19.3%) had one or more statistically signifi-
cant primary outcomes. There were 3934 (29.7%) trials classed as 
non-industry funded, 1569 (11.9%) as mixed and 7735 (58.4%) as 
industry funded. 12632 (95.4%) trials had a change in the primary 
outcome reported at initial registration; 12243 (92.5%) of these 
occurred after the trial completion date.
Statistical analysis showed that registration year, funding source and 
primary outcome change after trial completion were associated with 
the reporting a statistically significant primary outcome (Table 1). 
Mixed funding and increased year of registration (i.e. more recent 
calendar time) were associated with a decreased odds of report-
ing a statistically significant primary outcome. A primary outcome 
change and industry funding were associated with an increased 
odds of reporting a statistically significant primary outcome. We 
identified 123 trials that had inferiority in the title. Removing these 
studies from the analysis did not materially change the results.
When including study phase in the analysis (10633 studies with 
study phase data available), mixed funding and registration year 
became non-significant.
      Amendments from Version 1
We thank the reviewers for their comments. We have updated the 
manuscript with the following:
1) Defining how a primary outcome change was defined.
2) Highlighting the differences in effect direction for associated 
variables.
3) Providing an analysis controlling for study phase (results 
materially unchanged).
4) Performing the analysis after excluding potential non-inferiority 
trials (results materially unchanged).
See referee reports
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Conclusions
We found that the reporting of statistically significant outcomes 
on ClinicalTrials.gov was more likely for trials with primary out-
comes that had been changed and also those funded by industry. 
Previous studies have documented these associations5,6, and we 
confirm these using ClinicalTrials.gov data. There are limita-
tions to our analyses- we have not investigated in any detail the 
nature of the primary outcome change and the potential effect 
this would have on the statistical analysis/outcomes. As discussed 
previously3, some primary outcome changes that we have identified 
may be typographical/semantic and may not reflect actual changes 
to the nature of the outcome. We also did not look specifically to 
see whether a changed primary outcome was the one with a sta-
tistically significant finding, just whether a statistically significant 
finding was found for any primary outcome for the study. The vast 
majority of studies with results reported on ClinicalTrials.gov 
had a primary outcome change. This suggests that these trials are 
ones where the registrations have more diligent data updating. 
Nevertheless, this should be seen in equal measure for trials with 
and without statistically significant primary outcomes. In sum-
mary, funding source and primary outcome changes are associated 
with the reporting of statistically significant primary outcomes on 
ClinicalTrials.gov.
Data availability
F1000Research: Dataset 1. Dataset of funding source, primary out-
come changes and statistical significance of clinical trials registered 
on ClinicalTrials.org, 10.5256/f1000research.6312.d450567
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The authors have adequately addressed my concerns.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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The authors have clarified a number of the issues raised.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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 Janet Wale
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This Research Note is an extension of the authors' 2014 article (reference 3). It has a very clearly defined
question, whether changes made to the primary outcomes are associated with statistically significant
primary outcomes. The present data therefore includes only completed interventional studies on
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question, whether changes made to the primary outcomes are associated with statistically significant
primary outcomes. The present data therefore includes only completed interventional studies on
clinicaltrials.gov.
The second paragraph of the Methods section refers to the 2014 article. This is unhelpful, particularly as it
is not clear from the 2014 article how 'changes in primary outcomes' are defined. The final paragraph of
the Results section states that registration year, funding source and primary outcome change after trial
completion were associated with a significant primary outcome - yet these are in opposite directions; and
registration year is complex (looking at the data and 2014 article). That is brevity has taken over from
clarity.
Some of the limitations are included in the Conclusions: what exactly the changes were ('semantics'
versus actual change; whether the changed outcome was the statistically significant outcome reported).
The authors have not gone on to analyse their results by phase of trial; if the trials are randomised
controlled trials, or otherwise. Another important question is how many of the completed trials have
reported their results within a set timeframe (one year/two years), that is what about the trials that have
not reported their results?
Has the number of industry funded trials increased over time compared with mixed and public funded
trials? In plain language, what is the extent of the problem?
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
 30 March 2015Referee Report
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 Deborah Korenstein
Division of General Medicine, Mount Sinai School of Medicine, New York, NY, USA
Ramagopalan and colleagues have expanded on their previous work to assess the relationship between
changes in the primary endpoint on clinicaltrials.gov and both funding source and a “positive” trial result.
The authors found that changes to the primary listed endpoint were associated with both industry funding
and with a positive outcome.
 
Their sample included completed interventional clinical trials listed on clinicaltrials.gov. They defined trials
as having a positive result if they had a listed p-value <0.05. This may be problematic since it appears that
their sample included non-inferiority trials (though it is not clear how many) and for these trials a
non-significant p-value may indicate a “positive” (or at least non-inferior) result. Since there have been
growing numbers of non-inferiority trials published in recent years, this may be a substantial issue. The
authors may want to consider identifying non-inferiority trials and considering their results differently, or at
least reporting the prevalence of non-inferiority trials if possible.
 
Aside from this methodologic weakness the other methods are rather straightforward and clear. However,
the authors found that 95.4% of trials had changed the primary outcome at some point during the
registration period. In contrast, in their previous work the same authors found that 32% of trials registered
with clinicaltrials.gov had changed the primary endpoint. The reason for this dramatic difference is not
clear, and the authors do acknowledge that the vast majority of studies changed their primary endpoint
and that many of the changes may have been trivial. Further, in spite of this surprising finding the authors
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and that many of the changes may have been trivial. Further, in spite of this surprising finding the authors
still found significant associations. However, the near-total prevalence of changes to the primary endpoint
certainly suggests that changing a primary endpoint in the registry is highly routine and likely does not
reflect fundamental change to the study. This weakens the relevance of the findings.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
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